Early RA window of opportunity: how hard, how early? Commonsense reassurance from ESPOIR: to get good outcomes at 10y (DAS28≤2.6, HAQ≤0.5): - csDMARD early - bDMARD second line is okay, within first 1y+ (analysis weighted for subsequent Rx exposure) #ACR20 ABST1717 @RheumNow https://t.co/kG9WYUYYef